A U.S. subsidiary of generic drugmaker Laurus Labs has been issued a Form 483 with one observation by the U.S. Food and Drug Administration (U.S. FDA) after a post-marketing adverse drug experience (PADE) inspection.
The PADE inspection of the New Jersey-based wholly-owned foreign subsidiary Laurus Generics Inc. included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Laurus Labs marketed products worldwide.
The inspection was conducted for four days between January 13 and 21. “We have been issued a Form 483 with one observation and the company will address the said observation within stipulated timelines,” Laurus Labs said in a filing.
Published – January 22, 2025 06:40 pm IST
Denial of responsibility! Pioneer Newz is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.
